{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T17:46:21Z","timestamp":1780422381867,"version":"3.54.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.contraception.2010.01.011","type":"journal-article","created":{"date-parts":[[2010,2,20]],"date-time":"2010-02-20T04:39:04Z","timestamp":1266640744000},"page":"501-509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24\/4-day regimen"],"prefix":"10.1016","volume":"81","author":[{"given":"Cosima","family":"Brucker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Hedon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hok Sien","family":"The","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kornelia","family":"H\u00f6schen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natascha","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Christoph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2010.01.011_bb0005","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1136\/bmj.2.5703.231","article-title":"A statement by the committee on safety of drugs","volume":"2","author":"Combined oral contraceptives","year":"1970","journal-title":"Br Med J"},{"key":"10.1016\/j.contraception.2010.01.011_bb0010","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/bmj.2.5704.293","article-title":"R.C.O.G. statement on oral contraceptives","volume":"2","author":"Jeffcoate","year":"1970","journal-title":"Br Med J"},{"key":"10.1016\/j.contraception.2010.01.011_bb0015","first-page":"164","article-title":"[Recommendations for oral contraception. 20th Professional Meeting of the Zurich Discussion Group, April 1998]","volume":"38","author":"Birkhauser","year":"1998","journal-title":"Gynakol Geburtshilfliche Rundsch"},{"key":"10.1016\/j.contraception.2010.01.011_bb0020","first-page":"172","article-title":"[Recommendations for oral contraception. 24th meeting of the \u201cZurich Discussion Circle\u201d]","volume":"40","author":"Birkhauser","year":"2000","journal-title":"Gynakol Geburtshilfliche Rundsch"},{"key":"10.1016\/j.contraception.2010.01.011_bb0025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0010-7824(96)00137-0","article-title":"Shorter pill-free interval in combined oral contraceptives decreases follicular development","volume":"54","author":"Spona","year":"1996","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.01.011_bb0030","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2165\/00044011-200222040-00002","article-title":"Contraceptive efficacy and tolerability of chlormadinone acetate 2mg\/ethinylestradiol 0.03mg (Belara\u00ae). Results of a post-marketing surveillance study","volume":"22","author":"Schramm","year":"2002","journal-title":"Clin Drug Invest"},{"issue":"1","key":"10.1016\/j.contraception.2010.01.011_bb0035","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.contraception.2009.02.016","article-title":"Efficacy of an oral contraceptive containing ethinyl estradiol 0.03 mg and chlormadinone acetate 2 mg (EE\/CMA; Belara\u00ae) in moderate acne resolution: a randomised, double-blind, placebo-controlled phase III trial","volume":"80","author":"Plewig","year":"2009","journal-title":"Contraception."},{"key":"10.1016\/j.contraception.2010.01.011_bb0040","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0010-7824(02)00536-X","article-title":"A 12-month evaluation of the CMA-containing oral contraceptive Belara: efficacy, tolerability and anti-androgenic properties","volume":"67","author":"Schramm","year":"2003","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.01.011_bb0045","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/13625189909040809","article-title":"A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30 mu(g) ethinylestradiol and either 2 mg chlormadinone acetate or 150 mu(g) desogestrel","volume":"4","author":"Winkler","year":"1999","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2010.01.011_bb0050","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000051701","article-title":"Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE\/CMA (Belara) and EE\/LNG (Microgynon)","volume":"203","author":"Worret","year":"2001","journal-title":"Dermatology"},{"key":"10.1016\/j.contraception.2010.01.011_bb0055","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0010-7824(98)00008-0","article-title":"Efficacy and safety of the new antiandrogenic oral contraceptive Belara","volume":"57","author":"Zahradnik","year":"1998","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.01.011_bb0060","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.contraception.2007.12.007","volume":"77","author":"Zahradnik","year":"2008","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.01.011_bb0065","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.contraception.2007.03.014","article-title":"Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study","volume":"76","author":"Schramm","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.01.011_bb0070","first-page":"CD003989","article-title":"20 mcg versus >20 mcg estrogen combined oral contraceptives for contraception","author":"Gallo","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2010.01.011_bb0075","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0015-0282(99)00205-8","article-title":"Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity","volume":"72","author":"Sullivan","year":"1999","journal-title":"Fertil Steril"},{"key":"10.1016\/j.contraception.2010.01.011_bb0080","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2307\/2136191","article-title":"Measuring compliance among oral contraceptive users","volume":"28","author":"Potter","year":"1996","journal-title":"Fam Plann Perspect"},{"key":"10.1016\/j.contraception.2010.01.011_bb0085","series-title":"Pre-authorisation Evaluation of Medicines for Human Use. Guideline on clinical investigation of steroid contraceptives in women","first-page":"1","year":"2006"},{"key":"10.1016\/j.contraception.2010.01.011_bb0090","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2307\/2060159","article-title":"Application of the life table techniques to measurements of contraceptive effectiveness","volume":"3","author":"Potter","year":"1966","journal-title":"Demography"},{"key":"10.1016\/j.contraception.2010.01.011_bb0095","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0010-7824(86)90006-5","article-title":"The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction","volume":"34","author":"Belsey","year":"1986","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.01.011_bb0100","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2105\/AJPH.81.1.90","article-title":"Trends in the content and use of oral contraceptives in the United States, 1964\u201388","volume":"81","author":"Gerstman","year":"1991","journal-title":"Am J Public Health"},{"key":"10.1016\/j.contraception.2010.01.011_bb0105","series-title":"Modern oral contraception","author":"Wallach","year":"2000"},{"key":"10.1016\/j.contraception.2010.01.011_bb0110","first-page":"261","article-title":"Hormone withdrawal symptoms in oral contraceptive users","volume":"95","author":"Sulak","year":"2000","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2010.01.011_bb0115","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1067\/mob.2002.122988","article-title":"Acceptance of altering the standard 21-day\/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms","volume":"186","author":"Sulak","year":"2002","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2010.01.011_bb0120","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.contraception.2004.05.013","article-title":"Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone","volume":"70","author":"Bachmann","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.01.011_bb0125","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0002-9378(99)70362-5","article-title":"Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 microg levonorgestrel and 20 microg ethinyl estradiol (Alesse). North American Levonorgestrel Study Group (NALSG)","volume":"181","author":"Archer","year":"1999","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2010.01.011_bb0130","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00044011-200626030-00004","article-title":"Efficacy and safety of a low-dose 21-day combined oral contraceptive containing ethinylestradiol 20microg and drospirenone 3mg","volume":"26","author":"Cibula","year":"2006","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.contraception.2010.01.011_bb0135","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0010-7824(01)00232-3","article-title":"Double-blind, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day versus a 21-day low-dose oral contraceptive regimen containing 20 microg ethinyl estradiol and 75 microg gestodene","volume":"64","author":"Endrikat","year":"2001","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.01.011_bb0140","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0010-7824(95)00074-K","article-title":"Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation","volume":"51","author":"Rosenberg","year":"1995","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.01.011_bb0145","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.contraception.2006.03.022","article-title":"Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives","volume":"74","author":"Sabatini","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.01.011_bb0150","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/sim.4780100210","article-title":"The description of menstrual bleeding patterns: towards fewer measures","volume":"10","author":"Belsey","year":"1991","journal-title":"Stat Med"},{"issue":"Suppl. 2","key":"10.1016\/j.contraception.2010.01.011_bb0155","first-page":"9","article-title":"The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 \u03bcg and ethinylestradiol 15 \u03bcg","volume":"4","year":"1999","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2010.01.011_bb0160","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/00024677-200605020-00005","article-title":"A comparison of the cycle control, safety, and efficacy profile of a 21-day regimen of ethinylestradiol 20mug and drospirenone 3mg with a 21-day regimen of ethinylestradiol 20mug and desogestrel 150mug","volume":"5","author":"Gruber","year":"2006","journal-title":"Treat Endocrinol"},{"key":"10.1016\/j.contraception.2010.01.011_bb0165","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/13625189809167251","article-title":"A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 micrograms ethinylestradiol and either 150 micrograms desogestrel or 75 micrograms gestodene","volume":"3","author":"Serfaty","year":"1998","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2010.01.011_bb0170","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.contraception.2003.12.017","article-title":"Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol","volume":"69","author":"Winkler","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.01.011_bb0175","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.2165\/00003495-200565160-00007","article-title":"Low-dose ethinylestradiol\/levonorgestrel","volume":"65","author":"Dando","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.contraception.2010.01.011_bb0180","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2165\/00003495-200060040-00003","article-title":"Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms","volume":"60","author":"Godsland","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.contraception.2010.01.011_bb0185","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2217\/17455057.2.5.761","article-title":"Venous thrombosis and oral contraceptives: current status","volume":"2","author":"Tchaikovski","year":"2006","journal-title":"Women's Health"},{"key":"10.1016\/j.contraception.2010.01.011_bb0190","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1056\/NEJM200105173442007","article-title":"Oral contraceptives and the risk of venous thrombosis","volume":"344","author":"Vandenbroucke","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.contraception.2010.01.011_bb0195","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0010-7824(97)00010-3","article-title":"Multicenter study of endocrine function and plasma lipids and lipoproteins in women using oral contraceptives containing desogestrel progestin. UK Desogen Study Group","volume":"55","author":"Crook","year":"1997","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.01.011_bb0200","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0010-7824(01)00316-X","article-title":"An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 microg ethinyl estradiol and 100 microg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables","volume":"65","author":"Endrikat","year":"2002","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.01.011_bb0205","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.contraception.2003.11.003","article-title":"A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles","volume":"69","author":"Gaspard","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.01.011_bb0210","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0020-7292(00)85324-2","article-title":"A survey of American women regarding the use of oral contraceptives and weight gain [abstract]","volume":"70","author":"Wysocki","year":"2000","journal-title":"Int J Gynecol Obstet"},{"issue":"Suppl 1","key":"10.1016\/j.contraception.2010.01.011_bb0215","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/13625180500434913","article-title":"What women want and what their doctors need \u2014 how do women evaluate the quality of contraceptive methods and products introduced by their gynaecologist? A different perspective","volume":"10","author":"van de Weijer","year":"2005","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2010.01.011_bb0220","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0010-7824(01)00218-9","article-title":"A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation","volume":"64","author":"Sanders","year":"2001","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.01.011_bb0225","series-title":"Chlormadinonacetat bei Androgenisierungserscheinungen","first-page":"42","article-title":"Die Wirkung der Androgene auf das Zyklusgeschehen","author":"Mall-Haefeli","year":"1995"},{"key":"10.1016\/j.contraception.2010.01.011_bb0230","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1001\/archderm.1994.01690030040006","article-title":"Acne vulgaris in premenarchal girls. An early sign of puberty associated with rising levels of dehydroepiandrosterone","volume":"130","author":"Lucky","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.contraception.2010.01.011_bb0235","first-page":"75","article-title":"Postadolescent acne in women","volume":"48","author":"Kligman","year":"1991","journal-title":"Cutis"},{"key":"10.1016\/j.contraception.2010.01.011_bb0240","first-page":"CD004425","article-title":"Combined oral contraceptive pills for treatment of acne","author":"Arowojolu","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2010.01.011_bb0245","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.contraception.2007.07.002","article-title":"Noncontraceptive benefits of two combined oral contraceptives with antiandrogenic properties among adolescents","volume":"76","author":"Sabatini","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.01.011_bb0250","series-title":"Chemie und Pharmakologie von Chlormadinonacetat Chlormadinonacetat bei Androgenisierungserscheinungen","author":"Kuhl","year":"1995"},{"key":"10.1016\/j.contraception.2010.01.011_bb0255","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2165\/00003495-200363050-00003","article-title":"Progestogens with antiandrogenic properties","volume":"63","author":"Raudrant","year":"2003","journal-title":"Drugs"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782410000120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782410000120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T22:43:38Z","timestamp":1761432218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782410000120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0010782410000120"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2010.01.011","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24\/4-day regimen","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2010.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}